Cancer
Malignant Bladder Neoplasm
CI-CAN-00005866Explore in graph →
Top-level347 active trials10 approved drugs26 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer
CI-CAN-00005866Explore in graph →
Clinical trials
1,512 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (179)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04647981 | Diagnostic Performance Evaluation Study of the Xpert® Bladder Cancer Monitor Test.(Xpert Bladder) | completed | — | 320 | Clinique Beau SoleilOTHER | 1 | Feb 9, 2021 | clinicaltrials |
| NCT04738630 | Study of HX008 for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer | unknown | Phase 2 | 110 | Taizhou Hanzhong biomedical co. LTDINDUSTRY | 1 | Feb 4, 2021 |
| NCT03125200 | Study of ADCT-502 in Patients With Advanced Solid Tumors Withhuman Epidermal Growth Factor Receptor-2 (HER2) Expression | terminated | Phase 1 | 21 | ADC Therapeutics S.A.INDUSTRY | 2 | Feb 1, 2021 | clinicaltrials |
| NCT04726735 | Evaluation of PD-L1 Expression and Immune Infiltration in High-risk Non Muscle Invasive Bladder Cancer(IMMUN VESSIE) | completed | — | 100 | University Hospital, BordeauxOTHER | 1 | Jan 27, 2021 | clinicaltrials |
| NCT04723121 | Can We Predict of the Response of High Risk Non Muscle Invasive Bladder Cancer Patients to Intravesical Bacillus Calmette-Guerin? The Role of Immunological Markers | completed | N/A | 204 | Mansoura UniversityOTHER | 1 | Jan 25, 2021 | clinicaltrials |
| NCT04184232 | Treatment of Recurrent Bladder Cancer With Dendritic Cells | completed | Phase 2 | 17 | Institute of Biophysics and Cell Engineering of National Academy of Sciences of BelarusOTHER_GOV | 1 | Jan 22, 2021 | clinicaltrials |
| NCT04712201 | En Bloc Bladder Tumor Resection: Prospective Randomized Study | unknown | N/A | 300 | Fundacio PuigvertOTHER | 1 | Jan 15, 2021 | clinicaltrials |
| NCT02197897 | Evaluation the Treatment of Tamoxifen of Low/Intermediate Risk Bladder Tumors(BCTamoxifen) | completed | Phase 2 | 15 | Baylor College of MedicineOTHER | 1 | Jan 13, 2021 | clinicaltrials |
| NCT04687254 | Gender-related Characteristics of Bladder Cancer Treatment(BladderBLOG) | unknown | — | 500 | University of FlorenceOTHER | 1 | Dec 29, 2020 | clinicaltrials |
| NCT04686149 | a Genome-based Platform to Predict Patients That Can Achieve Bladder Preservation in Muscle Invasive Bladder Cancer Patients | unknown | — | 39 | Yonsei UniversityOTHER | 1 | Dec 28, 2020 | clinicaltrials |
| NCT04683536 | Bakircay University Cigli Training and Research Hospital(BUCEAH) | completed | — | 106 | Recep Tayyip Erdogan University Training and Research HospitalOTHER | 0 | Dec 24, 2020 | clinicaltrials |
| NCT02861196 | Research on the Combined-Modality Treatment Model of Bladder Preservation in Muscular Invasive Bladder Cancer | completed | N/A | 59 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Dec 17, 2020 | clinicaltrials |
| NCT03896958 | The PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor Ownership (Precision Oncology)(PIONEER) | unknown | — | 1,000 | SpeciCareINDUSTRY | 1 | Dec 4, 2020 | clinicaltrials |
| NCT04523025 | Nordic Cystectomy Study I - Neutrophil-lymphocyte Ratio (NLR)(NorCys-NLR) | unknown | — | 230 | Turku University HospitalOTHER_GOV | 1 | Nov 25, 2020 | clinicaltrials |
| NCT04523038 | Nordic Cystectomy Study II - Albumin(NorCys-Alb) | unknown | — | 1,700 | Turku University HospitalOTHER_GOV | 1 | Nov 25, 2020 | clinicaltrials |
| NCT04537221 | Nordic Cystectomy Study III - Transfusion(NorCys-Transf) | unknown | — | 1,700 | Turku University HospitalOTHER_GOV | 1 | Nov 25, 2020 | clinicaltrials |
| NCT04635566 | Pharmacological Enhancement for Nocturnal Incontinence in Orthotopic Bladder Substitute | completed | N/A | 120 | Mansoura UniversityOTHER | 1 | Nov 19, 2020 | clinicaltrials |
| NCT02788201 | Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma | completed | Phase 2 | 8 | National Cancer Institute (NCI)NIH | 1 | Nov 6, 2020 | clinicaltrials |
| NCT04610385 | Ileal Conduit Versus Cutaneous Ureterostomy After Radical Cystectomy | unknown | — | 40 | Assiut UniversityOTHER | 0 | Oct 30, 2020 | clinicaltrials |
| NCT04603612 | The Role of mRNA-based Urine Test (Xpert Bladder Cancer Monitor) in Predicting the Need for Second Look Biopsy After Transurethral Resection of Non Muscle-invasive Bladder Tumor. | completed | N/A | 254 | Mansoura UniversityOTHER | 1 | Oct 27, 2020 | clinicaltrials |
| NCT00341861 | Interdisciplinary Case-Control Study of Bladder Cancer in Spain | completed | — | 2,925 | National Cancer Institute (NCI)NIH | 1 | Oct 22, 2020 | clinicaltrials |
| NCT00003930 | Radiation Therapy and Combination Chemotherapy in Treating Patients With Stage II or Stage III Bladder Cancer | completed | Phase 1 / Phase 2 | 84 | Radiation Therapy Oncology GroupNETWORK | 2 | Oct 20, 2020 | clinicaltrials |
| NCT03639090 | Mass Spectrometry in Single Bladder Cancer Cells | completed | — | 2 | University of OklahomaOTHER | 1 | Oct 19, 2020 | clinicaltrials |
| NCT04402411 | Quadratus Lumborum Block vs Transversus Abdominis Plane Block in Bladder Cancer Surgeries | unknown | N/A | 63 | National Cancer Institute, EgyptOTHER | 1 | Oct 19, 2020 | clinicaltrials |
| NCT04588168 | Multi-parameter Magnetic Resonance Imaging Guides Precise Treatment of Urothelial Carcinoma | unknown | N/A | 100 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Oct 19, 2020 | clinicaltrials |
| NCT00478361 | Gemcitabine, Paclitaxel, Doxorubicin in Metastatic or Unresectable Bladder Cancer With Decreased Kidney Function | completed | Phase 2 | 40 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 9, 2020 | clinicaltrials |
| NCT03113266 | Safety and Efficacy of Toripalimab for Patients With Locally Advanced or Metastatic Bladder Urothelial Carcinoma | unknown | Phase 2 | 370 | Shanghai Junshi Bioscience Co., Ltd.OTHER | 1 | Sep 30, 2020 | clinicaltrials |
| NCT04286672 | Metadherin mRNA Expression in Bladder Cancer | unknown | — | 70 | Assiut UniversityOTHER | 0 | Sep 29, 2020 | clinicaltrials |
| NCT03138967 | Investigation of Sugammadex in Outpatient Urological Procedures | completed | Phase 4 | 54 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 22, 2020 | clinicaltrials |
| NCT02555163 | Laser En Bloc Resection Of Bladder Tumor (HoLERBT) VS. Conventional Transurethral Resection Of Bladder Tumors (cTURBT)(HoLERBT) | completed | N/A | 100 | Mansoura UniversityOTHER | 1 | Sep 18, 2020 | clinicaltrials |
| NCT00749892 | Erlotinib Hydrochloride in Treating Participants With Muscle Invasive or Recurrent Urothelial Cancer | completed | Phase 2 | 34 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 10, 2020 | clinicaltrials |
| NCT02346955 | Study of CM-24 (MK-6018) Alone and In Combination With Pembrolizumab (MK-3475) in Participants With Selected Advanced or Recurrent Malignancies (MK-6018-001) | terminated | Phase 1 | 27 | Famewave Ltd.INDUSTRY | 2 | Aug 27, 2020 | clinicaltrials |
| NCT04525781 | Clinicoepidimiological Study and Clinical Outcome in Patients With Urinary Bladder Cancer | unknown | — | 150 | Assiut UniversityOTHER | 0 | Aug 25, 2020 | clinicaltrials |
| NCT03498196 | A Window of Opportunity Trial: Avelumab in Non-metastatic Muscle Invasive Bladder Cancer | terminated | Phase 1 / Phase 2 | 1 | Baylor College of MedicineOTHER | 1 | Aug 24, 2020 | clinicaltrials |
| NCT03719300 | Codex: Study of Inodiftagene Vixteplasmid (BC-819) in Unresponsive NMIBC | terminated | Phase 2 | 32 | Anchiano Therapeutics Israel Ltd.INDUSTRY | 1 | Aug 19, 2020 | clinicaltrials |
| NCT00088946 | Erlotinib and Green Tea Extract (Polyphenon® E) in Preventing Cancer Recurrence in Former Smokers Who Have Undergone Surgery for Bladder Cancer | completed | Phase 2 | 17 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jul 31, 2020 | clinicaltrials |
| NCT03167151 | Pembrolizumab in Intermediate Risk Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)(PemBla) | terminated | Phase 1 / Phase 2 | 6 | University of OxfordOTHER | 1 | Jul 31, 2020 | clinicaltrials |
| NCT04493489 | Propranolol Adjuvant Treatment of Bladder Cancer | unknown | Phase 2 | 242 | Central South UniversityOTHER | 0 | Jul 30, 2020 | clinicaltrials |
| NCT04219046 | Evaluation of Naloxegol in the Prevention of POI After Cystectomy(ANTAGOCYST) | unknown | Phase 2 | 102 | Institut Paoli-CalmettesOTHER | 0 | Jul 28, 2020 | clinicaltrials |
| NCT02092948 | Phase I Study to evaluate124I-A11 PSCA Minibody in Patients With Metastatic Prostate, Bladder and Pancreatic Cancer | completed | Phase 1 | 8 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jul 27, 2020 | clinicaltrials |
| NCT02688348 | Quality of Life After Bladder-Preservation Chemotherapy and Radiation Therapy in Patients With Muscle-Invasive Bladder Cancer | withdrawn | N/A | 0 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jul 24, 2020 | clinicaltrials |
| NCT03672240 | Study of APL-1202 in Non-Muscle Invasive Bladder Cancer Patients Who Are Resistant to One Induction Course of BCG Treatment(NMIBC) | completed | Phase 1 / Phase 2 | 6 | Asieris Pharmaceutical Technologies Co., Ltd.INDUSTRY | 1 | Jul 20, 2020 | clinicaltrials |
| NCT00342875 | The New England Bladder Cancer Study | completed | — | 2,681 | National Cancer Institute (NCI)NIH | 1 | Jul 15, 2020 | clinicaltrials |
| NCT03254888 | Autophagy Bladder Cancer | unknown | — | 150 | Assiut UniversityOTHER | 1 | Jul 8, 2020 | clinicaltrials |
| NCT02169284 | Erlotinib Hydrochloride in Treating Patients With Bladder Cancer Undergoing Surgery | terminated | Phase 2 | 50 | National Cancer Institute (NCI)NIH | 1 | Jul 7, 2020 | clinicaltrials |
| NCT04073160 | TRIO Bladder: A Study of Durvalumab Plus Tremelimumab Followed by Concurrent Durvalumab Plus Bladder Radiation in Muscle-Invasive Bladder Cancer(TRIO Bladder) | withdrawn | Phase 1 | 0 | Daniel George, MDOTHER | 1 | Jul 7, 2020 | clinicaltrials |
| NCT04256616 | Immunogenic Cell Death as a Novel Mechanism of Mitomycin C Activity in Bladder Cancer(ICH-MIM-01) | unknown | — | 110 | Istituto Clinico HumanitasOTHER | 1 | Jul 7, 2020 | clinicaltrials |
| NCT03147599 | Mebeverine For 1st Year Daytime And Nocturnal Incontinence After Orthotopic W-Ileal Neobladders | completed | Phase 4 | 110 | Mansoura UniversityOTHER | 1 | Jun 30, 2020 | clinicaltrials |
| NCT02662166 | MRI in Clinical Staging and Estimation of Treatment Response in Bladder Cancer(MIB) | completed | N/A | 50 | Turku University HospitalOTHER_GOV | 1 | Jun 17, 2020 | clinicaltrials |
| NCT02447549 | Study of Tumour Focused Radiotherapy for Bladder Cancer(RAIDER) | active not recruiting | Phase 2 | 345 | Institute of Cancer Research, United KingdomOTHER | 3 | Jun 9, 2020 | clinicaltrials |
Data updated 24 days agoSource updated Feb 9, 2021source: clinicaltrials